



IN THE DISCLOSURE

No changes.

IN THE CLAIMS

Please amend the claim set as set out below consistent with the PCT filing and the amendment of May 25, 2000 (attached) filed in response to the Written Opinion of March 30, 2000. The claims have been placed in proper format for U.S. prosecution to avoid improper multiple dependencies. The subject matter of claims 1 to 11 is identical to the subject matter of claims 1 to 7 in the PCT amended claim set dated May 25, 2000.

The following claims therefor stand in the application:

1. A pharmaceutical tablet comprising a shell in which is imbedded two smaller tablets covered by material of the shell of the pharmaceutical tablet, one of which tablet comprises an NSAID and the other of which tablets comprises misoprostol, whereby the two smaller tablets are not exposed to the environment of the surface of the pharmaceutical tablet.
2. The pharmaceutical tablet of Claim 1 wherein the smaller tablet containing the NSAID is enteric coated.
3. A pharmaceutical tablet as in Claim 1 or 2 wherein the NSAID is piroxicam.
4. A pharmaceutical tablet as in Claim 1 or 2 wherein the NSAID is selected from diclofenac and salts thereof.

5. A pharmaceutical tablet as in Claim 3 wherein the amount of piroxicam is from about 10 mg to about 20 mg.
6. A pharmaceutical tablet as in Claim 4 wherein the amount of diclofenac or a salt thereof is from about 25 mg to about 75 mg.

Please amend the claim as follows:

7. (Amended) The [A] pharmaceutical tablet [as in any] of Claim[s] [1 to 6] 1 or 2 wherein the amount of misoprostol is about 200 μ g.

Please add the following claims:

8. The pharmaceutical tablet of Claim 3 wherein the amount of misoprostol is about 200 μ g.
9. The pharmaceutical tablet of Claim 4 wherein the amount of misoprostol is about 200 μ g.
10. The pharmaceutical tablet of Claim 5 wherein the amount of misoprostol is about 200 μ g.
11. The pharmaceutical tablet of Claim 6 wherein the amount of misoprostol is about 200 μ g.